

RADIONUCLIDE THERANOSTICS: THE POTENTIAL IN NEUROENDOCRINE TUMOURS

KEY SPEAKER



Dr Philip E Harris
PhD FRCP FRSB

Philip E Harris trained in endocrinology at the University of Wales College of Medicine, St Bartholomew's Hospital, London, the University of Newcastle-upon-Tyne and Massachusetts General Hospital, Boston.

In 1994, he was appointed Senior Lecturer and Honorary Consultant Endocrinologist at King's College Hospital, London. Although his main role is now in the pharmaceutical industry, he remains clinically active. In 2001, he was appointed Director Adult Endocrinology at Pharmacia and subsequently Senior Director and Head of Endocrinology Clinical Development at Pfizer. Dr Harris is currently Vice President Scientific Affairs at Ipsen Biopharma. His main focus is in the development of strategically aligned early opportunities in neuroendocrine disease, with academic and industrial collaborations and the identification of opportunities for in-licensing and acquisition. Dr Harris has a key role in the development of Ipsen's strategy in radiotheranostics, with products currently in development for neuroendocrine tumours and pancreatic cancer.

PROGRAMME

4.30pm Registration
5.00pm Presentation
5.20pm Interactive Discussion
6.00pm End of lecture

NMSS.ORG.SG

EVENT DETAILS

WHEN

November 11th, 2016
4.30pm – 6.00pm

WHERE

Seminar Room L1-S3
Level 1, Academia
(SGH)

20 College Road, 169856

RSVP

RSVP by

04 NOVEMBER 2016

to

Ms Shirley Tay

at

secretariat@nmss.org.sg

ORGANISED BY

